Invasive fungal disease (IFD) remains a major complication of allogeneic hematopoietic stem cell transplantation (alloHSCT) and is associated with high mortality in patients undergoing alloHSCT

The literature reported here analyzes a cross-sectional observational AFHEM study to describe the use of antifungal drugs in real-world clinical practice in alloHSCT recipients hospitalized in a French hematology ward

n n

Overall, 119 (81%) patients received systemic antifungal therapy; of these, 95 (80%) patients received antifungal prophylaxis

119 (81%) patients received systemic antifungal therapy; of these, 95 (80%) patients received antifungal prophylaxis

Table 1: Frequency of use of systemic antifungal strategies based on preimplantation data (N = 95)

Table 1: Frequency of use of systemic antifungal strategies based on preimplantation data (N = 95) Table 1: Frequency of use of systemic antifungal strategies based on preimplantation data (N = 95)

The proportion of patients receiving systemic antifungal therapy was similar regardless of transplant time, neutropenia, and graft-versus-host disease status

n n n

Regarding empiric therapy, 9 (69%) patients received caspofungin, 2 (15%) received liposomal amphotericin B, and the remaining 2 (15%) received azoles (oral fluconazole or intravenous voriconazole)

n n

Table 2: Characteristics of hospitalized patients treated with different systemic antifungal strategies during the 5-day observation period

Table 2: Characteristics of hospitalized patients treated with different systemic antifungal strategies during the 5-day observation period Table 2: Characteristics of hospitalized patients treated with different systemic antifungal strategies during the 5-day observation period Table 2: Treatment with different systemic antifungal strategies during the 5-day observation period characteristics of hospitalized patients

Of the 95 patients who received antifungal prophylaxis, 56 (59%) had relapsed or refractory disease and 38 (40%) had neutropenia

Of the 13 patients treated empirically, 8 (62%) had relapsed or refractory disease and 2 (15%) had a history of IFD

Eleven patients were treated according to a preemptive or curative strategy; the majority ( n=10; 91%) were in relapsed or refractory disease, and four (36%) had experienced an IFD episode

n

This study has several limitations

This study has several limitations

Unlike earlier studies, the AFHEM study showed that prophylaxis appears to be the main antifungal strategy used in French alloHSCT recipients

Original source:

Original source:

Michallet M, El Cheikh J, Herbrecht R, Yakoub-Agha I, Caillot D, Gangneux JP.

Michallet M, El Cheikh J, Herbrecht R, Yakoub-Agha I, Caillot D, Gangneux JP.
Systemic antifungal strategies in allogeneic hematopoietic stem cell recipients hospitalized in french hematology units: a post-hoc analysis of the cross-sectional observational AFHEM study.
BMC Infect Dis.
2022 Apr 9;22(1):352.
doi: 10.
1186/s12879-022-07216-6.
PMID: 35397492; PMCID: PMC8994341.
Michallet M, El Cheikh J, Herbrecht R, Yakoub-Agha I, Caillot D, Gangneux JP.
Systemic antifungal strategies in allogeneic hematopoietic stem cell recipients hospitalized in french hematology units: a post-hoc analysis of the cross-sectional observational AFHEM study.
BMC Infect Dis.
2022 Apr 9;22(1):352.
doi: 10.
1186/s12879-022-07216-6.
PMID: 35397492; PMCID: PMC8994341.


Leave a message here